The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

George I. Papakostas

Massachusetts General Hospital

Harvard Medical School

15 Parkman Street

WACC#812

USA

[email]@partners.org

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, WACC#812, USA. 2010 - 2011
  • Center for Treatment-Resistant Depression, Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, USA. 2003 - 2010

References

  1. Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram. Papakostas, G.I., Larsen, K. Eur. Arch. Psychiatry. Clin. Neurosci (2011) [Pubmed]
  2. S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trial. Papakostas, G.I., Mischoulon, D., Shyu, I., Alpert, J.E., Fava, M. Am. J. Psychiatry (2010) [Pubmed]
  3. 5HT1A-mediated stimulation of cortisol release in major depression: use of non-invasive cortisol measurements to predict clinical response. Papakostas, G.I., Chuzi, S.E., Sousa, J.L., Fava, M. Eur. Arch. Psychiatry. Clin. Neurosci (2010) [Pubmed]
  4. Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. Papakostas, G.I., Charles, D., Fava, M. World J. Biol. Psychiatry (2010) [Pubmed]
  5. Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study. Papakostas, G.I., Clain, A., Ameral, V.E., Baer, L., Brintz, C., Smith, W.T., Londborg, P.D., Glaudin, V., Painter, J.R., Fava, M. Int. Clin. Psychopharmacol (2010) [Pubmed]
  6. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Papakostas, G.I., Fava, M. Eur. Neuropsychopharmacol (2009) [Pubmed]
  7. Evidence for S-adenosyl-L-methionine (SAM-e) for the treatment of major depressive disorder. Papakostas, G.I. J. Clin. Psychiatry (2009) [Pubmed]
  8. Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies. Papakostas, G.I., Cooper-Kazaz, R., Appelhof, B.C., Posternak, M.A., Johnson, D.P., Klibanski, A., Lerer, B., Fava, M. Int. Clin. Psychopharmacol (2009) [Pubmed]
  9. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. Papakostas, G.I. J. Clin. Psychiatry (2009) [Pubmed]
  10. Major depressive disorder: psychosocial impairment and key considerations in functional improvement. Papakostas, G.I. Am. J. Manag. Care (2009) [Pubmed]
  11. Tolerability of modern antidepressants. Papakostas, G.I. J. Clin. Psychiatry (2008) [Pubmed]
  12. Use of atypical antipsychotics for treatment-resistant major depressive disorder. Papakostas, G.I., Shelton, R.C. Curr. Psychiatry. Rep (2008) [Pubmed]
  13. A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Papakostas, G.I., Nelson, J.C., Kasper, S., Möller, H.J. Eur. Neuropsychopharmacol (2008) [Pubmed]
  14. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder. Papakostas, G.I., McGrath, P., Stewart, J., Charles, D., Chen, Y., Mischoulon, D., Dording, C., Fava, M. Psychiatry. Res (2008) [Pubmed]
  15. Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Papakostas, G.I., Fava, M., Thase, M.E. Biol. Psychiatry (2008) [Pubmed]
  16. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of major depressive disorder with high levels of anxiety (anxious depression): a pooled analysis of 10 studies. Papakostas, G.I., Stahl, S.M., Krishen, A., Seifert, C.A., Tucker, V.L., Goodale, E.P., Fava, M. J. Clin. Psychiatry (2008) [Pubmed]
  17. Efficacy of bupropion and the selective serotonin reuptake inhibitors in the treatment of anxiety symptoms in major depressive disorder: a meta-analysis of individual patient data from 10 double-blind, randomized clinical trials. Papakostas, G.I., Trivedi, M.H., Alpert, J.E., Seifert, C.A., Krishen, A., Goodale, E.P., Tucker, V.L. J. Psychiatr. Res (2008) [Pubmed]
  18. Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder. Papakostas, G.I., Fava, M. Dialogues. Clin. Neurosci (2008) [Pubmed]
  19. A meta-analysis of clinical trials comparing mirtazapine with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Papakostas, G.I., Homberger, C.H., Fava, M. J. Psychopharmacol. (Oxford) (2008) [Pubmed]
  20. Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder. Papakostas, G.I., Petersen, T., Homberger, C.H., Green, C.H., Smith, J., Alpert, J.E., Fava, M. Ann. Clin. Psychiatry (2007) [Pubmed]
  21. Limitations of contemporary antidepressants: tolerability. Papakostas, G.I. J. Clin. Psychiatry (2007) [Pubmed]
  22. Antidepressant dose reduction and the risk of relapse in major depressive disorder. Papakostas, G.I., Perlis, R.H., Seifert, C., Fava, M. Psychother. Psychosom (2007) [Pubmed]
  23. Relative antidepressant efficacy of bupropion and the selective serotonin reuptake inhibitors in major depressive disorder: gender-age interactions. Papakostas, G.I., Kornstein, S.G., Clayton, A.H., Soares, C.N., Hallett, L.A., Krishen, A., Tucker, V.L. Int. Clin. Psychopharmacol (2007) [Pubmed]
  24. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. A replication of findings with the use of a double-blind, placebo-controlled trial of Hypericum perforatum versus fluoxetine. Papakostas, G.I., Crawford, C.M., Scalia, M.J., Fava, M. Neuropsychobiology (2007) [Pubmed]
  25. A survey of five antidepressant properties influencing clinician's treatment choices in MDD. Papakostas, G.I., Hallett, L.A., Smith, J., Tossani, E., Mascarini, A., Burns, A.M., Birnbaum, R.J., Fava, M., Alpert, J.E. Neuropsychiatr. Dis. Treat (2007) [Pubmed]
  26. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Papakostas, G.I., Thase, M.E., Fava, M., Nelson, J.C., Shelton, R.C. Biol. Psychiatry (2007) [Pubmed]
  27. A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Papakostas, G.I., Fava, M. Eur. Psychiatry (2007) [Pubmed]
  28. Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: a pooled survival analysis of 7 double-blind, randomized clinical trials. Papakostas, G.I., Montgomery, S.A., Thase, M.E., Katz, J.R., Krishen, A., Tucker, V.L. J. Clin. Psychiatry (2007) [Pubmed]
  29. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. Papakostas, G.I., Shelton, R.C., Smith, J., Fava, M. J. Clin. Psychiatry (2007) [Pubmed]
  30. A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. Papakostas, G.I., Fava, M. Eur. Neuropsychopharmacol (2007) [Pubmed]
  31. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. Papakostas, G.I., Petersen, T., Sklarsky, K.G., Nierenberg, A.A., Alpert, J.E., Fava, M. Psychiatry. Res (2007) [Pubmed]
  32. Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. Papakostas, G.I., Miller, K.K., Petersen, T., Sklarsky, K.G., Hilliker, S.E., Klibanski, A., Fava, M. J. Clin. Psychiatry (2006) [Pubmed]
  33. Adjunctive atomoxetine for residual fatigue in major depressive disorder. Papakostas, G.I., Petersen, T.J., Burns, A.M., Fava, M. J. Psychiatr. Res (2006) [Pubmed]
  34. Dopaminergic-based pharmacotherapies for depression. Papakostas, G.I. Eur. Neuropsychopharmacol (2006) [Pubmed]
  35. The combination of duloxetine and bupropion for treatment-resistant major depressive disorder. Papakostas, G.I., Worthington, J.J., Iosifescu, D.V., Kinrys, G., Burns, A.M., Fisher, L.B., Homberger, C.H., Mischoulon, D., Fava, M. Depress. Anxiety (2006) [Pubmed]
  36. Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors. Papakostas, G.I., Nutt, D.J., Hallett, L.A., Tucker, V.L., Krishen, A., Fava, M. Biol. Psychiatry (2006) [Pubmed]
  37. A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder. Papakostas, G.I., Fava, M. Can. J. Psychiatry (2006) [Pubmed]
  38. Obesity among outpatients with major depressive disorder. Papakostas, G.I., Petersen, T., Iosifescu, D.V., Burns, A.M., Nierenberg, A.A., Alpert, J.E., Rosenbaum, J.F., Fava, M. Int. J. Neuropsychopharmacol. (2005) [Pubmed]
  39. The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. Papakostas, G.I., Petersen, T., Lebowitz, B.D., Mischoulon, D., Ryan, J.L., Nierenberg, A.A., Bottiglieri, T., Alpert, J.E., Rosenbaum, J.F., Fava, M. Int. J. Neuropsychopharmacol. (2005) [Pubmed]
  40. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. Papakostas, G.I., Petersen, T.J., Kinrys, G., Burns, A.M., Worthington, J.J., Alpert, J.E., Fava, M., Nierenberg, A.A. J. Clin. Psychiatry (2005) [Pubmed]
  41. A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic. Papakostas, G.I., Petersen, T.J., Green, C., Iosifescu, D.V., Yeung, A.S., Nierenberg, A.A., Fava, M., Posternak, M.A. Ann. Clin. Psychiatry (2005) [Pubmed]
  42. Quality of life assessments in major depressive disorder: a review of the literature. Papakostas, G.I., Petersen, T., Mahal, Y., Mischoulon, D., Nierenberg, A.A., Fava, M. Gen. Hosp. Psychiatry (2004) [Pubmed]
  43. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. Papakostas, G.I., Petersen, T.J., Nierenberg, A.A., Murakami, J.L., Alpert, J.E., Rosenbaum, J.F., Fava, M. J. Clin. Psychiatry (2004) [Pubmed]
  44. Cholesterol in mood and anxiety disorders: review of the literature and new hypotheses. Papakostas, G.I., Ongür, D., Iosifescu, D.V., Mischoulon, D., Fava, M. Eur. Neuropsychopharmacol (2004) [Pubmed]
  45. Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder. Papakostas, G.I., Petersen, T.J., Iosifescu, D.V., Summergrad, P., Sklarsky, K.G., Alpert, J.E., Nierenberg, A.A., Fava, M. J. Clin. Psychiatry (2004) [Pubmed]
  46. Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder. Papakostas, G.I., Petersen, T., Hughes, M.E., Nierenberg, A.A., Alpert, J.E., Fava, M. Psychiatry. Res (2004) [Pubmed]
  47. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression. Papakostas, G.I., Petersen, T., Mischoulon, D., Ryan, J.L., Nierenberg, A.A., Bottiglieri, T., Rosenbaum, J.F., Alpert, J.E., Fava, M. J. Clin. Psychiatry (2004) [Pubmed]
  48. Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy. Papakostas, G.I., Petersen, T., Mischoulon, D., Green, C.H., Nierenberg, A.A., Bottiglieri, T., Rosenbaum, J.F., Alpert, J.E., Fava, M. J. Clin. Psychiatry (2004) [Pubmed]
  49. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. Papakostas, G.I., Petersen, T., Denninger, J.W., Tossani, E., Pava, J.A., Alpert, J.E., Nierenberg, A.A., Fava, M. J. Clin. Psychopharmacol (2004) [Pubmed]
  50. Somatic symptoms in treatment-resistant depression. Papakostas, G.I., Petersen, T., Denninger, J., Sonawalla, S.B., Mahal, Y., Alpert, J.E., Nierenberg, A.A., Fava, M. Psychiatry. Res (2003) [Pubmed]
  51. Serum cholesterol in treatment-resistant depression. Papakostas, G.I., Petersen, T., Sonawalla, S.B., Merens, W., Iosifescu, D.V., Alpert, J.E., Fava, M., Nierenberg, A.A. Neuropsychobiology (2003) [Pubmed]
  52. Serum cholesterol and serotonergic function in major depressive disorder. Papakostas, G.I., Petersen, T., Mischoulon, D., Hughes, M.E., Alpert, J.E., Nierenberg, A.A., Rosenbaum, J.F., Fava, M. Psychiatry. Res (2003) [Pubmed]
  53. Axis III disorders in treatment-resistant major depressive disorder. Papakostas, G.I., Petersen, T., Iosifescu, D.V., Roffi, P.A., Alpert, J.E., Rosenbaum, J.F., Fava, M., Nierenberg, A.A. Psychiatry. Res (2003) [Pubmed]
  54. A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed. Papakostas, G.I., Petersen, T., Worthington, J.J., Roffi, P.A., Alpert, J.E., Fava, M., Nierenberg, A.A. Int. Clin. Psychopharmacol (2003) [Pubmed]
  55. S-adenosyl-methionine in depression: a comprehensive review of the literature. Papakostas, G.I., Alpert, J.E., Fava, M. Curr. Psychiatry. Rep (2003) [Pubmed]
  56. Psychiatric comorbidity as a predictor of clinical response to nortriptyline in treatment-resistant major depressive disorder. Papakostas, G.I., Petersen, T.J., Farabaugh, A.H., Murakami, J.L., Pava, J.A., Alpert, J.E., Fava, M., Nierenberg, A.A. J. Clin. Psychiatry (2003) [Pubmed]
  57. Treatment-related adverse events and outcome in a clinical trial of fluoxetine for major depressive disorder. Papakostas, G.I., Petersen, T., Denninger, J.W., Montoya, H.D., Nierenberg, A.A., Alpert, J.E., Fava, M. Ann. Clin. Psychiatry (2003) [Pubmed]
 
WikiGenes - Universities